Communication for applicants Reporting of notifications of suspected unexpected serious adverse reactions (SUSARs) and the Development Safety Update Report (DSUR) in clinical trials during the quarantine period

In view of the current situation with coronavirus disease, the State Expert Center of the Ministry of Health of Ukraine considers it acceptable to send the notifications of SUSAR and DSURs in clinical trials of medicinal products to the e-mail address of Preclinical and Clinical Trial Materials Expert Evaluation Department clinic@dec.gov.ua or in paper form by post to the address: 14, Anton Tsedik St., 03057 Kyiv.